Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
19
PRTA Quote, Financials, Valuation and Earnings
Last price:
$9.73
Seasonality move
:
5.27%
Day range:
$9.23 - $9.74
52-week range:
$4.32 - $16.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.25x
P/B ratio:
1.77x
Volume:
237.4K
Avg. volume:
724.3K
1-year change:
-37.08%
Market cap:
$521.6M
Revenue:
$135.2M
EPS (TTM):
-$5.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRTA
Prothena Corp. Plc
|
$6.6M | -$0.54 | -68.6% | -57.29% | $20.33 |
|
AMRN
Amarin Corp. Plc
|
$43.1M | -- | -18% | -100% | $12.00 |
|
GHRS
GH Research Plc
|
-- | -$0.23 | -- | -62.11% | $30.38 |
|
ITRM
Iterum Therapeutics Plc
|
-- | -$0.24 | -- | -49.47% | $5.50 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.17% | 106.38% | $213.00 |
|
MURA
Mural Oncology Plc
|
-- | -$0.59 | -- | -81.57% | $5.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRTA
Prothena Corp. Plc
|
$9.69 | $20.33 | $521.6M | -- | $0.00 | 0% | 44.25x |
|
AMRN
Amarin Corp. Plc
|
$13.75 | $12.00 | $285.9M | -- | $0.00 | 0% | 7.17x |
|
GHRS
GH Research Plc
|
$12.79 | $30.38 | $793M | -- | $0.00 | 0% | -- |
|
ITRM
Iterum Therapeutics Plc
|
$0.31 | $5.50 | $14M | -- | $0.00 | 0% | 29.49x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$170.80 | $213.00 | $10.4B | 15.09x | $0.00 | 0% | 2.51x |
|
MURA
Mural Oncology Plc
|
$2.04 | $5.00 | $35.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRTA
Prothena Corp. Plc
|
2.99% | 1.493 | 1.73% | 6.43x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.841 | 1.98% | 2.35x |
|
GHRS
GH Research Plc
|
0.2% | 2.392 | 0.07% | 27.72x |
|
ITRM
Iterum Therapeutics Plc
|
128.01% | 0.805 | 112.75% | 1.78x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
|
MURA
Mural Oncology Plc
|
6.04% | 2.518 | 9.89% | 5.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRTA
Prothena Corp. Plc
|
$1.5M | -$39.8M | -65.85% | -67.47% | -1646.42% | -$43.2M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
GHRS
GH Research Plc
|
-$89K | -$16.5M | -16.82% | -16.86% | -- | -$14.5M |
|
ITRM
Iterum Therapeutics Plc
|
$15K | -$7.7M | -98.23% | -- | -1982.31% | -$7.9M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
MURA
Mural Oncology Plc
|
-$800K | -$4M | -104.55% | -111% | -- | -$18.5M |
Prothena Corp. Plc vs. Competitors
-
Which has Higher Returns PRTA or AMRN?
Amarin Corp. Plc has a net margin of -1513.09% compared to Prothena Corp. Plc's net margin of -15.58%. Prothena Corp. Plc's return on equity of -67.47% beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp. Plc60.95% -$0.68 $304.1M AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About PRTA or AMRN?
Prothena Corp. Plc has a consensus price target of $20.33, signalling upside risk potential of 109.84%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -12.15%. Given that Prothena Corp. Plc has higher upside potential than Amarin Corp. Plc, analysts believe Prothena Corp. Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp. Plc2 2 0 AMRNAmarin Corp. Plc0 1 1 -
Is PRTA or AMRN More Risky?
Prothena Corp. Plc has a beta of -0.099, which suggesting that the stock is 109.869% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.246%.
-
Which is a Better Dividend Stock PRTA or AMRN?
Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or AMRN?
Prothena Corp. Plc quarterly revenues are $2.4M, which are smaller than Amarin Corp. Plc quarterly revenues of $49.4M. Prothena Corp. Plc's net income of -$36.5M is lower than Amarin Corp. Plc's net income of -$7.7M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 44.25x versus 7.17x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M
-
Which has Higher Returns PRTA or GHRS?
GH Research Plc has a net margin of -1513.09% compared to Prothena Corp. Plc's net margin of --. Prothena Corp. Plc's return on equity of -67.47% beat GH Research Plc's return on equity of -16.86%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp. Plc60.95% -$0.68 $304.1M GHRSGH Research Plc-- -$0.23 $292M -
What do Analysts Say About PRTA or GHRS?
Prothena Corp. Plc has a consensus price target of $20.33, signalling upside risk potential of 109.84%. On the other hand GH Research Plc has an analysts' consensus of $30.38 which suggests that it could grow by 137.58%. Given that GH Research Plc has higher upside potential than Prothena Corp. Plc, analysts believe GH Research Plc is more attractive than Prothena Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp. Plc2 2 0 GHRSGH Research Plc5 0 0 -
Is PRTA or GHRS More Risky?
Prothena Corp. Plc has a beta of -0.099, which suggesting that the stock is 109.869% less volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTA or GHRS?
Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or GHRS?
Prothena Corp. Plc quarterly revenues are $2.4M, which are larger than GH Research Plc quarterly revenues of --. Prothena Corp. Plc's net income of -$36.5M is lower than GH Research Plc's net income of -$14M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 44.25x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M GHRSGH Research Plc-- -- -- -$14M
-
Which has Higher Returns PRTA or ITRM?
Iterum Therapeutics Plc has a net margin of -1513.09% compared to Prothena Corp. Plc's net margin of -2302.31%. Prothena Corp. Plc's return on equity of -67.47% beat Iterum Therapeutics Plc's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp. Plc60.95% -$0.68 $304.1M ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M -
What do Analysts Say About PRTA or ITRM?
Prothena Corp. Plc has a consensus price target of $20.33, signalling upside risk potential of 109.84%. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 1651.04%. Given that Iterum Therapeutics Plc has higher upside potential than Prothena Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Prothena Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp. Plc2 2 0 ITRMIterum Therapeutics Plc1 0 0 -
Is PRTA or ITRM More Risky?
Prothena Corp. Plc has a beta of -0.099, which suggesting that the stock is 109.869% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191.032%.
-
Which is a Better Dividend Stock PRTA or ITRM?
Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or ITRM?
Prothena Corp. Plc quarterly revenues are $2.4M, which are larger than Iterum Therapeutics Plc quarterly revenues of $390K. Prothena Corp. Plc's net income of -$36.5M is lower than Iterum Therapeutics Plc's net income of -$9M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 44.25x versus 29.49x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M ITRMIterum Therapeutics Plc29.49x -- $390K -$9M
-
Which has Higher Returns PRTA or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -1513.09% compared to Prothena Corp. Plc's net margin of 22.33%. Prothena Corp. Plc's return on equity of -67.47% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp. Plc60.95% -$0.68 $304.1M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About PRTA or JAZZ?
Prothena Corp. Plc has a consensus price target of $20.33, signalling upside risk potential of 109.84%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 24.71%. Given that Prothena Corp. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Prothena Corp. Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp. Plc2 2 0 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is PRTA or JAZZ More Risky?
Prothena Corp. Plc has a beta of -0.099, which suggesting that the stock is 109.869% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.
-
Which is a Better Dividend Stock PRTA or JAZZ?
Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or JAZZ?
Prothena Corp. Plc quarterly revenues are $2.4M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Prothena Corp. Plc's net income of -$36.5M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 44.25x versus 2.51x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M
-
Which has Higher Returns PRTA or MURA?
Mural Oncology Plc has a net margin of -1513.09% compared to Prothena Corp. Plc's net margin of --. Prothena Corp. Plc's return on equity of -67.47% beat Mural Oncology Plc's return on equity of -111%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp. Plc60.95% -$0.68 $304.1M MURAMural Oncology Plc-- -$0.21 $58.7M -
What do Analysts Say About PRTA or MURA?
Prothena Corp. Plc has a consensus price target of $20.33, signalling upside risk potential of 109.84%. On the other hand Mural Oncology Plc has an analysts' consensus of $5.00 which suggests that it could grow by 194.12%. Given that Mural Oncology Plc has higher upside potential than Prothena Corp. Plc, analysts believe Mural Oncology Plc is more attractive than Prothena Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp. Plc2 2 0 MURAMural Oncology Plc0 1 0 -
Is PRTA or MURA More Risky?
Prothena Corp. Plc has a beta of -0.099, which suggesting that the stock is 109.869% less volatile than S&P 500. In comparison Mural Oncology Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTA or MURA?
Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mural Oncology Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Mural Oncology Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or MURA?
Prothena Corp. Plc quarterly revenues are $2.4M, which are larger than Mural Oncology Plc quarterly revenues of --. Prothena Corp. Plc's net income of -$36.5M is lower than Mural Oncology Plc's net income of -$3.7M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Mural Oncology Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 44.25x versus -- for Mural Oncology Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M MURAMural Oncology Plc-- -- -- -$3.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
